AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38573263 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (non-HF)
Number of subjects: 217
Study 38573333 — intervention group
Group type: EXPERIMENTAL
Intervention: Autofluorescence-guided hemithyroidectomy
Number of subjects: 170
Study 38573333 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemithyroidectomy
Number of subjects: 170
Study 38573367 — intervention group
Group type: EXPERIMENTAL
Intervention: Engineered TOF-R features
Number of subjects: 524
Study 38573367 — intervention group
Group type: COMPARATOR
Intervention: Basic features
Number of subjects: 524
Study 38573403 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional communication and support by nurse facilitators
Number of subjects: 385
Study 38573403 — intervention group
Group type: COMPARATOR
Intervention: Standard communication by ICU clinicians
Number of subjects: 385
Study 38573466 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity-centric approach with anti-obesity medications
Number of subjects: 74
Study 38573466 — intervention group
Group type: COMPARATOR
Intervention: Usual-care approach
Number of subjects: 74
Study 38573482 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Number of subjects: 137
Study 38573517 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab 210 mg monthly
Number of subjects: 0
Study 38573517 — intervention group
Group type: COMPARATOR
Intervention: Comparator (Placebo in FRAME, Alendronate 70 mg weekly in ARCH)
Number of subjects: 0
Study 38573597 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy dose 51 to 60 Gy
Number of subjects: 95
Study 38573597 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy dose 50 Gy or lower
Number of subjects: 95
Study 38573597 — intervention group
Group type: COMPARATOR
Intervention: Higher radiotherapy dose (70 Gy as reference)
Number of subjects: 95
Study 38573634 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient portal training intervention (touch, in-person [high])
Number of subjects: 2892
Study 38573634 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient portal functionality intervention (full functionality)
Number of subjects: 2892
Study 38573634 — intervention group
Group type: COMPARATOR
Intervention: Built-in video tutorial (low)
Number of subjects: 2892
Study 38573634 — intervention group
Group type: COMPARATOR
Intervention: Limited subset of functions (lite)
Number of subjects: 2892
Study 38573638 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 31
Study 38573638 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 31
Study 38573638 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 31
Study 38573638 — intervention group
Group type: COMPARATOR
Intervention: Baseline comparison
Number of subjects: 31
Study 38573638 — intervention group
Group type: COMPARATOR
Intervention: Physical Activity
Number of subjects: 31
Study 38573643 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus durvalumab (FD arm)
Number of subjects: 96
Study 38573643 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus durvalumab and tremelimumab (FDT arm)
Number of subjects: 96
Study 38573708 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg daily
Number of subjects: 202
Study 38573708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 38573713 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-day insight (Vipassana) mindfulness meditation retreats
Number of subjects: 143
Study 38573713 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 143
Study 38573759 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab biosimilar Ogivri
Number of subjects: 53
Study 38573759 — intervention group
Group type: COMPARATOR
Intervention: Herceptin (historical cohort)
Number of subjects: 53
Study 38573872 — intervention group
Group type: EXPERIMENTAL
Intervention: Infigratinib 125 mg by mouth once daily for 21 days (28-day cycle) for 2 cycles
Number of subjects: 14
Study 38573915 — intervention group
Group type: EXPERIMENTAL
Intervention: RIF+AMX/CLV
Number of subjects: 0
Study 38573915 — intervention group
Group type: EXPERIMENTAL
Intervention: RIF+CLA+AMX/CLV
Number of subjects: 0
Study 38573915 — intervention group
Group type: COMPARATOR
Intervention: RIF+CLA
Number of subjects: 0
Study 38573925 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrashift isatuximab assay
Number of subjects: 141
Study 38573925 — intervention group
Group type: COMPARATOR
Intervention: Standard IFE
Number of subjects: 141
Study 38574044 — intervention group
Group type: EXPERIMENTAL
Intervention: HIPEC with doxorubicin
Number of subjects: 6
Study 38574312 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (40 mg/m) and Gemcitabine with Intensity-Modulated Radiation Therapy (IMRT)
Number of subjects: 57
Study 38574330 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38574351 — intervention group
Group type: EXPERIMENTAL
Intervention: HEMOPHAR e-learning program
Number of subjects: 502
Study 38574400 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal white matter hyperintensities (WMH)
Number of subjects: 0
Study 38574400 — intervention group
Group type: EXPERIMENTAL
Intervention: Occipital white matter hyperintensities (WMH)
Number of subjects: 0
Study 38574400 — intervention group
Group type: EXPERIMENTAL
Intervention: Amyloid beta (Aβ) pathology
Number of subjects: 0
Study 38574739 — intervention group
Group type: EXPERIMENTAL
Intervention: ZF2202-A booster
Number of subjects: 0
Study 38574739 — intervention group
Group type: COMPARATOR
Intervention: BA.2.86
Number of subjects: 0
Study 38574739 — intervention group
Group type: COMPARATOR
Intervention: JN.1
Number of subjects: 0
Study 38574739 — intervention group
Group type: COMPARATOR
Intervention: EG.5
Number of subjects: 0
Study 38574757 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor-based dual antiplatelet therapy (DAPT) for 1 month
Number of subjects: 2617
Study 38574757 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued ticagrelor from 1 to 12 months
Number of subjects: 2617
Study 38574757 — intervention group
Group type: EXPERIMENTAL
Intervention: De-escalation to clopidogrel from 1 to 12 months
Number of subjects: 2617
Study 38574757 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from ticagrelor to clopidogrel after 1 month
Number of subjects: 2617
Study 38574853 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional psychiatric treatments (INTs) including electroconvulsive therapy, transcranial magnetic stimulation, and esketamine
Number of subjects: 493
Study 38574853 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional psychiatric treatments (INTs)
Number of subjects: 493
Study 38574853 — intervention group
Group type: COMPARATOR
Intervention: No INT
Number of subjects: 493
Study 38574873 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)
Number of subjects: 208
Study 38574876 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care consultation (PCC)
Number of subjects: 32
Study 38574978 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (n = 10)
Number of subjects: 32
Study 38574978 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 32
Study 38574978 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n = 7)
Number of subjects: 32
Study 38575049 — intervention group
Group type: EXPERIMENTAL
Intervention: CHESS system intervention group
Number of subjects: 1600
Study 38575049 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 1600
Study 38575104 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative pain neuroscience education (PPNE)
Number of subjects: 120
Study 38575409 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-based combinations (IO)
Number of subjects: 200
Study 38575409 — intervention group
Group type: COMPARATOR
Intervention: Tyrosine kinase inhibitors (TKIs)
Number of subjects: 200
Study 38575433 — intervention group
Group type: EXPERIMENTAL
Intervention: IndoVac
Number of subjects: 4050
Study 38575433 — intervention group
Group type: COMPARATOR
Intervention: Covovax
Number of subjects: 4050
Study 38575449 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 6006
Study 38575449 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 6006
Study 38575674 — intervention group
Group type: EXPERIMENTAL
Intervention: Baecke questionnaire total score
Number of subjects: 0
Study 38575674 — intervention group
Group type: EXPERIMENTAL
Intervention: Baecke questionnaire without Sport Index
Number of subjects: 0
Study 38575674 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported physical activity
Number of subjects: 0
Study 38575674 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure-time MET-Index
Number of subjects: 0
Study 38575729 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg at week 0, week 4, and every 12 weeks thereafter through week 52
Number of subjects: 55
Study 38575731 — intervention group
Group type: EXPERIMENTAL
Intervention: Tepotinib 500 mg once daily
Number of subjects: 106
Study 38575854 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin (7 mg weekly for six months)
Number of subjects: 15
Study 38575887 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education intervention (educational waiting room posters and flyers)
Number of subjects: 26
Study 38575887 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26
Study 38575887 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 26
Study 38575888 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based resilience training (MBRT)
Number of subjects: 0
Study 38575888 — intervention group
Group type: COMPARATOR
Intervention: Attention control (stress management education [SME])
Number of subjects: 0
Study 38575888 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 0
Study 38575929 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent behavioral intervention consisting of prescriber education via academic detailing, standardized patient post-extraction instructions, and blister packs of acetaminophen and ibuprofen.
Number of subjects: 33
Study 38575929 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control group).
Number of subjects: 33
Study 38575929 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent behavioral intervention.
Number of subjects: 33
Study 38575938 — intervention group
Group type: EXPERIMENTAL
Intervention: BETTER HEALTH intervention delivered by public health nurses
Number of subjects: 38
Study 38575938 — intervention group
Group type: EXPERIMENTAL
Intervention: BETTER HEALTH intervention
Number of subjects: 38
Study 38575945 — intervention group
Group type: EXPERIMENTAL
Intervention: JoyPop app (4 weeks, at least twice daily usage)
Number of subjects: 0
Study 38575945 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (monitoring)
Number of subjects: 0
Study 38575945 — intervention group
Group type: EXPERIMENTAL
Intervention: JoyPop app
Number of subjects: 0
Study 38575952 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchestra in Class (OC)
Number of subjects: 150
Study 38575952 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Arts (VA)
Number of subjects: 150
Study 38575952 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 150
Study 38576007 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% initial oxygen concentration
Number of subjects: 0
Study 38576007 — intervention group
Group type: COMPARATOR
Intervention: Lower oxygen concentration (not specified)
Number of subjects: 0
Study 38576033 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic oligosaccharides
Number of subjects: 0
Study 38576033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38576046 — intervention group
Group type: EXPERIMENTAL
Intervention: Active robot-assisted resistance training
Number of subjects: 488
Study 38576046 — intervention group
Group type: COMPARATOR
Intervention: Passive robot-assisted sham training
Number of subjects: 488
Study 38576165 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative Approach to Fluid Therapy
Number of subjects: 100
Study 38576165 — intervention group
Group type: COMPARATOR
Intervention: Liberal Approach to Fluid Therapy
Number of subjects: 100
Study 38576178 — intervention group
Group type: EXPERIMENTAL
Intervention: BRV 50 mg/day
Number of subjects: 449
Study 38576178 — intervention group
Group type: EXPERIMENTAL
Intervention: BRV 200 mg/day
Number of subjects: 449
Study 38576178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449
Study 38577337 — intervention group
Group type: EXPERIMENTAL
Intervention: TYRP1-TCB (RO7293583) administered in escalating doses (0.045 to 0.4 mg)
Number of subjects: 20
Study 38577523 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonoid intervention for 2 weeks
Number of subjects: 60
Study 38577523 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 38577571 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized natural progesterone protocol
Number of subjects: 150
Study 38577571 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist protocol
Number of subjects: 150
Study 38577574 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 40 mg/28 days intramuscularly for acromegaly or pasireotide 600 μg subcutaneously twice daily for Cushing's disease.
Number of subjects: 249
Study 38577574 — intervention group
Group type: EXPERIMENTAL
Intervention: Incretin-based therapy or insulin (for those requiring additional/alternative antihyperglycemic medication).
Number of subjects: 249
Study 38577574 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (for those who did not need antihyperglycemic medication).
Number of subjects: 249
Study 38577701 — intervention group
Group type: EXPERIMENTAL
Intervention: MRSA surgical site infection (SSI)
Number of subjects: 0
Study 38577701 — intervention group
Group type: EXPERIMENTAL
Intervention: Country-specific incidence rates of MRSA SSI
Number of subjects: 0
Study 38577701 — intervention group
Group type: EXPERIMENTAL
Intervention: Centres with established ABS and ID consultation programmes
Number of subjects: 0
Study 38577931 — intervention group
Group type: EXPERIMENTAL
Intervention: ACURATE neo2
Number of subjects: 296
Study 38577931 — intervention group
Group type: COMPARATOR
Intervention: ACURATE neo
Number of subjects: 296
Study 38578158 — intervention group
Group type: EXPERIMENTAL
Intervention: High postoperative lactate (≥ 4 mmol/L)
Number of subjects: 132
Study 38578289 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Dignity Inventory (PDI-CZ)
Number of subjects: 258
Study 38578289 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function, self-sufficiency, vision, and hearing assessments
Number of subjects: 258
Study 38578289 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Depression Scale
Number of subjects: 258
Study 38578289 — intervention group
Group type: EXPERIMENTAL
Intervention: Social involvement items
Number of subjects: 258
Study 38578289 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of self-sufficiency and pain
Number of subjects: 258
Study 38578352 — intervention group
Group type: EXPERIMENTAL
Intervention: B-type sutured ileostomy
Number of subjects: 124
Study 38578352 — intervention group
Group type: COMPARATOR
Intervention: Traditional ileostomy (Control)
Number of subjects: 124
Study 38578394 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG) at a dosage of 10 mg/kg as intravenous infusion on days 1 and 8 of 21-day cycles
Number of subjects: 529
Study 38578394 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG)
Number of subjects: 529
Study 38578394 — intervention group
Group type: EXPERIMENTAL
Intervention: Total antibody (tAB)
Number of subjects: 529
Study 38578394 — intervention group
Group type: EXPERIMENTAL
Intervention: Free SN-38
Number of subjects: 529
Study 38578534 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger participants (≤40 years)
Number of subjects: 0
Study 38578534 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education, being male, and earning $20,000-$39,999
Number of subjects: 0
Study 38578534 — intervention group
Group type: EXPERIMENTAL
Intervention: Somali immigrants who are younger, more formally educated, male, and/or earn $20,000-$39,000
Number of subjects: 0
Study 38578537 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab-containing chemotherapy
Number of subjects: 143
Study 38578640 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated RNI (40.05 Gy/15 fractions)
Number of subjects: 50
Study 38578640 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventionally fractionated RNI (50 Gy/25 fractions)
Number of subjects: 50
Study 38578640 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (PreMRT and RNI followed by mastectomy and IMBR)
Number of subjects: 50
Study 38578666 — intervention group
Group type: EXPERIMENTAL
Intervention: eCDSS plus usual care
Number of subjects: 0
Study 38578666 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study 38578667 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group 1 (EG1) - 4 sessions of VR-based self-conversations with ConVRself after intensive motivational interviewing training.
Number of subjects: 68
Study 38578667 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group 2 (EG2) - 4 VR-based sessions led by a virtual counselor with a prerecorded discourse, undergoing embodiment technique.
Number of subjects: 68
Study 38578667 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - Treatment as usual from the obesity unit.
Number of subjects: 68
Study 38578673 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracking and Reducing Alcohol Consumption (4-session MI intervention)
Number of subjects: 405
Study 38578673 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracking and Reducing Alcohol Consumption and Environmental Risk (EMI with MI and real-time messaging)
Number of subjects: 405
Study 38578673 — intervention group
Group type: COMPARATOR
Intervention: Smartphone-based alcohol monitoring-only control group
Number of subjects: 405
Study 38578675 — intervention group
Group type: EXPERIMENTAL
Intervention: TeNDER technological tool for health and self-care
Number of subjects: 38
Study 38578686 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided lifestyle intervention (12-week duration, including 1 virtual group session, digital tools, access to self-paced web- and mobile-based content, and 12 weekly health risk text messages)
Number of subjects: 14
Study 38578690 — intervention group
Group type: EXPERIMENTAL
Intervention: MOBICPR intervention group (MOBICPR-IG)
Number of subjects: 43
Study 38578690 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (WL-CG)
Number of subjects: 43
Study 38578720 — intervention group
Group type: EXPERIMENTAL
Intervention: Emicizumab prophylaxis
Number of subjects: 177
Study 38579294 — intervention group
Group type: EXPERIMENTAL
Intervention: Lp(a) levels in patients with LAA stroke
Number of subjects: 743
Study 38579294 — intervention group
Group type: EXPERIMENTAL
Intervention: Log10 Lp(a) levels
Number of subjects: 743
Study 38579294 — intervention group
Group type: COMPARATOR
Intervention: Lp(a) levels in patients with diabetes
Number of subjects: 743
Study 38579297 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of elemental oral iron as ferrous sulfate
Number of subjects: 15
Study 38579297 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of elemental oral iron as ferrous sulfate
Number of subjects: 15
Study 38579297 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg of elemental oral iron as ferrous sulfate
Number of subjects: 15
Study 38579297 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 mg of elemental oral iron as ferrous sulfate
Number of subjects: 15
Study 38579300 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital intervention (evaluation of inhalation technique and PIF, provision of a written guide, therapeutic education)
Number of subjects: 93
Study 38579300 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 93
Study 38579300 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital intervention
Number of subjects: 93
Study 38579309 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual oncology care plus the palliative care intervention (SENS)
Number of subjects: 58
Study 38579309 — intervention group
Group type: COMPARATOR
Intervention: Usual oncology care alone
Number of subjects: 58
Study 38579315 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID-based pain control (oral acetaminophen and intravenous ketorolac)
Number of subjects: 96
Study 38579315 — intervention group
Group type: COMPARATOR
Intervention: Opioid-based pain control
Number of subjects: 96
Study 38579579 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Number of subjects: 43
Study 38579579 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous training
Number of subjects: 43
Study 38579579 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study 38579696 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38579729 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammation score based on identified inflammatory proteins
Number of subjects: 109
Study 38579729 — intervention group
Group type: EXPERIMENTAL
Intervention: SERPINA9, TACI, and TARC
Number of subjects: 109
Study 38579940 — intervention group
Group type: EXPERIMENTAL
Intervention: DOAC score
Number of subjects: 14672
Study 38579940 — intervention group
Group type: COMPARATOR
Intervention: VKA
Number of subjects: 14672
Study 38580007 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum uric acid levels
Number of subjects: 1014
Study 38580007 — intervention group
Group type: COMPARATOR
Intervention: Low serum uric acid levels
Number of subjects: 1014
Study 38580007 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum uric acid levels (dose-response analysis)
Number of subjects: 1014
Study 38580133 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection (ESD) for absolute indication EGC
Number of subjects: 149